helicobacter%20pylori%20infection
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.

Follow Up

Patient should be re-tested after a minimum of 4 weeks after treatment

  • It is advisable to confirm eradication of H pylori with a post-treatment UBT, monoclonal stool test or upper endoscopy
    • Antisecretory drugs especially PPIs should be discontinued at least 1-2 weeks prior to post-test, while Bismuth compounds and antibiotics should be stopped at least 4 weeks prior to test 
  • Patients with either gastric ulcers or complicated duodenal ulcers should have a repeat endoscopy and biopsy, UBT, or stool antigen test to rule out malignancy
  • In patients with persistent H pylori infection, a culture and sensitivity may be done before retreatment, except when considering a Bismuth-based quadruple therapy
  • Serology is not used in determining treatment response
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 6 days ago

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.